Wednesday, July 2, 2025

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

Related stories

Blaize Raises $56M for Edge AI in Southeast Asia’s Infra

Blaize, a leader in edge AI computing, has secured...

Formant F3 Adds Gen AI, Agentic Reasoning to Robot Ops

Formant has announced the debut of F3, an AI-native...

CustomerInsights.AI Launches ciATHENA, an AI Platform for Pharma Analytics

CIAI announced the launch of ciATHENA, a next generation Agentic...

PhaseV Unveils ClinOps AI for Smarter Trial Site Picks

Powered by Causal AI and Real-Time Patient-Level Data and...

Accenture Acquires SYSTEMA to Boost Semiconductor Automation

Accenture has acquired SYSTEMA, a provider of software solutions...
spot_imgspot_img

Multi-year collaboration will enable development of complex, cutting-edge cell therapies and armoring technologies for solid tumor targets

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center announced a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors. In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

Under the collaboration agreement, Generate:Biomedicines and Roswell Park will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors. In recent years, CAR T-cells have seen remarkable successes for the treatment of liquid tumors, such as leukemia and lymphoma, including FDA approvals; however, successful treatment of solid tumors remains a major challenge for the field.

The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients. The collaboration continues the significant momentum associated with the recently announced expansion, supported in part by New York State funds, that will make Roswell Park’s Current Good Manufacturing Practice (cGMP) facilities the largest academic cell therapy center in the United States.

Also Read: Aktana acquires Tact.ai’s Field Engagement and Conversational AI technology

“This is a powerful combination that brings together Roswell Park’s world-leading expertise in cell therapy manufacturing and our technology and computational power,” said Generate:Biomedicines’ Executive Vice President, Research & Development, Alex Snyder, M.D. “Dr. Brentjens – whose lab played a foundational role in development of the currently approved therapies – together with Dr. Davila and their team are among the world’s leading experts in cell therapy. Together we will deliver novel CAR T-cell therapeutics rapidly to change outcomes for patients with advanced solid tumors.”

“This collaboration with Generate:Biomedicines will allow us to harness the power of generative AI to rapidly advance our research to make groundbreaking cancer therapies for patients who are in need of new treatment options,” said Renier Brentjens, M.D., Ph.D., Deputy Director and Chair of Medicine at Roswell Park Comprehensive Cancer Center.

“Getting these complex new therapies to patients can often be a lengthy and complicated process requiring versatile solutions. By tapping into The Generate Platform, we see a great opportunity to efficiently and effectively advance innovative oncology treatments from idea to clinic,” adds Marco Davila, M.D., Ph.D., Senior Vice President and Associate Director for Translational Research, Department of Medicine, Roswell Park Comprehensive Cancer Center.

Under the agreement terms, Generate:Biomedicines and Roswell Park will share research and development expenses as well as profits generated through commercialization of products that emerge from the collaboration. It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img